Prascend is the first and only medicine available in the US that is fully approved by the FDA to treat pituitary pars intermedia dysfunction (more commonly called PPID or equine Cushing's disease) in horses. As part of the FDA approval process, Prascend was rigorously tested to prove its safety and effectiveness in reducing signs of PPID in horses.
When you treat your horse with Prascend under guidance from your veterinarian, you can rest assured that you're giving your equine friend a medicine that is tested and trusted to work safely and consistently. These study results really mean that you can feel confident giving your horse Prascend to control signs of PPID! It may help get your horse back to his healthy, happy self again.
For the control of clinical signs associated with Pituitary Pars Intermedia Dysfunction (equine Cushing’s Disease) in horses.
Administer orally at a starting dose of 2 mcg/kg once daily. Dosage may be adjusted to effect, not to exceed 4 mcg/kg daily. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when Prascend Tablets are split or crushed. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. The tablets are scored and the calculated dosage should be provided to the nearest one-half tablet increment.
Please follow veterinarian's directions.
|Body weight ||2 mcg/kg dosage ||4 mcg/kg dosage |
|136 - 340 kg|
(300 - 749 lb)
|0.5 tablet||1 tablet|
|341 - 568 kg|
(750 - 1,249 lb)
|1 tablet||2 tablets|
|569 - 795 kg|
(1,250 - 1,749 lb)
|1.5 tablets||3 tablets|
|796 - 1,022 kg|
(1,750 - 2,249 lb)
|2 tablets||4 tablets|
Store at or below 25°C (77°F). Keep away from children and pets.
Do not use in horses intended for human consumption.
Not for use in humans. Keep this and all medications out of the reach of children. Prascend should not be administered by persons who have had adverse reactions to ergotamine or other ergot derivatives. Pregnant or lactating women should wear gloves when administering this product. It has been reported that pergolide tablets may cause eye irritation, an irritating smell, or headache when Prascend Tablets are split or crushed. Prascend Tablets should not be crushed due to the potential for increased human exposure and care should be taken to minimize exposure when splitting tablets. Consult a physician in case of accidental ingestion by humans.
Prascend is contraindicated in horses with hypersensitivity to pergolide mesylate or other ergot derivatives.
Treatment with Prascend may cause inappetance.
The use of Prascend in breeding, pregnant, or lactating horses has not been evaluated. The effects of pergolide mesylate on breeding, pregnant, or lactating horses are not known; however, the pharmacologic action of pergolide mesylate suggests that it may interfere with reproductive functions such as lactation.
Prascend is approximately 90% associated with plasma proteins. Use caution if administering Prascend with other drugs that affect protein binding. Dopamine antagonists, such as neuroleptics (phenothiazines, domperidone) or metoclopramide, ordinarily should not be administered concurrently with Prascend (a dopamine agonist) since these agents may diminish the effectiveness of Prascend.
A total of 122 horses treated with Prascend Tablets for six months were included in a field study safety analysis.
The adverse reactions noted were decreased appetite, lameness, diarrhea/loose stool, colic, lethargy, abnormal weight loss, laminitis, heart murmur, death, tooth disorder, skin abscess, musculoskeletal pain, behavior change.
Horses with PPID will also benefit from an overall excellent general health care along with individual nutritionrecommendations from your veterinarian.
Following recommendations from your veterinarian
According to recommendations from your veterinarian
Prascend comes in convenient packaging:
Important Safety Information